Skip to main content

Table 4 Treatment’s characteristics and outcomes

From: Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients

 

All

(n = 131)

Hemopathy

(n = 58)

Solid tumors

(n = 29)

Endocrinopathies (n = 16)

Other (n = 28)

Hyperhydration, n (%)

124 (94.6)

53 (91.3)

29 (100)

16 (100)

26 (92.8)

 Crystalloid, n (%)

119 (90)

50 (87.7)

29 (100)

16 (100)

24 (85.7)

 Volume at day 1 (L/day)

3 [2, 3]

3 [2, 3]

3 [2.5; 3]

3.25 [2.25; 4]

2 [2, 3]

 Side effect: pulmonary edema, n (%)

11 (8.3)

9 (17)

2 (6.8)

0

0

Bisphosphonate infusion, n (%)

103 (78.6)

49 (84)

26 (89.6)

12 (75)

17 (60.7)

 Second infusion, n (%)

13 (10)

5 (10.2)

5 (19.2)

0

3 (10.7)

Corticosteroids, n (%)

65 (50)

49 (84.4)

10 (34.5)

0

6 (21.4)

Furosemide, n (%)

13 (10)

6 (10.3)

1 (3.4)

0

6 (21.4)

Calcimimetics, n (%)

6 (5)

0

1 (3.4)

5 (31)

0

Calcitonin, n (%)

12 (9)

4 (6.8)

5 (17.2)

1 (6.3)

2 (7.1)

Renal replacement therapy, n (%)

25 (19)

20 (34.4)

3 (10.3)

1 (6.3)

1 (3.6)

 Duration of RRT (d)

5 [2.5; 7]

5 [2.5; 6]

3

3

11

Vasopressor, n (%)

6 (4.5)

5 (8.6)

0

0

1 (3.5)

Mechanical ventilation, n (%)

10 (7.6)

6 (10.3)

3 (10.3)

0

1 (3.5)

ICU mortality, n (%)

13 (9.9)

4 (6.8)

6 (20.6)

1 (6.3)

2 (7.1)

Hospital mortality, n %)

26 (21.3)

10 (17.2)

13 (44.8)

1 (6.3)

2 (7.1)

  1. Values for categorical variables are given as number (percentage); values for continuous variables, as median [interquartile range]
  2. ICU intensive-care unit, RRT renal replacement therapy